Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.75 |
| ▸ | CXCR1 | P25024 | 19/20 | 0.75 |
| ▸ | CCR7 | P32248 | 1/20 | 0.74 |
| ▸ | CCR6 | P51684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927207 | 1.00 | CXCR2 (0.75) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263679 | 0.92 | CXCR2 (0.78) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262759 | 0.91 | CXCR2 (0.76) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262781 | 0.91 | CXCR2 (0.76) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL14270873 | 0.90 | CXCR2 (0.77) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL19351994 | 0.88 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL2019927 | 0.88 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL949803 | 0.88 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL30515684 | 0.88 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL14270871 | 0.86 | CXCR2 (0.69) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041107-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008005570-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR5, CXCR3, CCR2 | CXCR2 14/4885CXCR1 9/4885CCR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.